Methyltransferase DNMT3B in leukemia

References

• Chaudry SF, Chevassut TJ. Epigenetic guardian: a review of the DNA methyltransferase DNMT3A in acute myeloid leukaemia and clonal haematopoiesis. Biomed Res Int. 2017;2017:5473197.
   PubMedGoogle Scholar
• Lyko F. The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat Rev Genet. 2018;19(2):81–92.
   PubMed Web of Science ®Google Scholar
• Gruenbaum Y, Cedar H, Razin A. Substrate and sequence specificity of a eukaryotic DNA methylase. Nature. 1982;295(5850):620–622.
   PubMed Web of Science ®Google Scholar
• Okano M, Bell DW, Haber DA, et al. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99(3):247–257.
   PubMed Web of Science ®Google Scholar
• Lei H, Oh SP, Okano M, et al. De novo DNA cytosine methyltransferase activities in mouse embryonic stem cells. Development. 1996;122(10):3195–3205.
   PubMed Web of Science ®Google Scholar
• Jeltsch A, Jurkowska RZ. Allosteric control of mammalian DNA methyltransferases - a new regulatory paradigm. Nucleic Acids Res. 2016;44(18):8556–8575.
   PubMed Web of Science ®Google Scholar
• Singh RK, Mallela RK, Hayes A, et al. Dnmt1, Dnmt3a and Dnmt3b cooperate in photoreceptor and outer plexiform layer development in the mammalian retina. Exp Eye Res. 2017;159:132–146.
   PubMed Web of Science ®Google Scholar
• Fatemi M, Hermann A, Gowher H, et al. Dnmt3a and Dnmt1 functionally cooperate during de novo methylation of DNA. Eur J Biochem. 2002;269(20):4981–4984.
   PubMedGoogle Scholar
• Rhee I, Bachman KE, Park BH, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 2002;416(6880):552–556.
   PubMed Web of Science ®Google Scholar
• Kim GD, Ni J, Kelesoglu N, et al. Co-operation and communication between the human maintenance and de novo DNA (cytosine-5) methyltransferases. EMBO J. 2002;21(15):4183–4195.
   PubMed Web of Science ®Google Scholar
• Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. Lancet. 2018;391(10129):1524–1537.
   PubMed Web of Science ®Google Scholar
• Koschmieder S, Vetrie D. Epigenetic dysregulation in chronic myeloid leukaemia: a myriad of mechanisms and therapeutic options. Semin Cancer Biol. 2018;51:180–197.
   PubMed Web of Science ®Google Scholar
• Mansouri L, Wierzbinska JA, Plass C, et al. Epigenetic deregulation in chronic lymphocytic leukemia: clinical and biological impact. Semin Cancer Biol. 2018;51:1–11.
   PubMed Web of Science ®Google Scholar
• Nordlund J, Syvanen AC. Epigenetics in pediatric acute lymphoblastic leukemia. Semin Cancer Biol. 2018;51:129–138.
   PubMed Web of Science ®Google Scholar
• Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593–606.
   PubMed Web of Science ®Google Scholar
• Benetatos L, Vartholomatos G. On the potential role of DNMT1 in acute myeloid leukemia and myelodysplastic syndromes: not another mutated epigenetic driver. Ann Hematol. 2016;95(10):1571–1582.
   PubMed Web of Science ®Google Scholar
• Vicente-Duenas C, Gonzalez-Herrero I, Sehgal L, et al. Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemia. Leukemia. 2018;33:249–278.
   PubMed Web of Science ®Google Scholar
• Brunetti L, Gundry MC, Goodell MA. DNMT3A in leukemia. Cold Spring Harb Perspect Med. 2017;7(2):a030320.
   PubMed Web of Science ®Google Scholar
• Yang L, Rau R, Goodell MA. DNMT3A in haematological malignancies. Nat Rev Cancer. 2015;15(3):152–165.
   PubMed Web of Science ®Google Scholar
• Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424–2433.
   PubMed Web of Science ®Google Scholar
• Challen GA. Dominating the negative: how DNMT3A mutations contribute to AML pathogenesis. Cell Stem Cell. 2017;20(1):7–8.
   PubMed Web of Science ®Google Scholar
• Spencer DH, Russler-Germain DA, Ketkar S, et al. CpG island hypermethylation mediated by DNMT3A is a consequence of AML progression. Cell. 2017;168(5):801–816.
   PubMed Web of Science ®Google Scholar
• Loghavi S, Zuo Z, Ravandi F, et al. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol. 2014;7:74.
   PubMed Web of Science ®Google Scholar
• Bullinger L, Dohner K, Dohner H. Genomics of acute myeloid leukemia diagnosis and pathways. J Clin Oncol. 2017;35(9):934–946.
   PubMed Web of Science ®Google Scholar
• Ostronoff F, Othus M, Ho PA, et al. Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report. Leukemia. 2013;27(1):238–241.
   PubMed Web of Science ®Google Scholar
• Gale RE, Lamb K, Allen C, et al. Simpson's Paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia. J Clin Oncol. 2015;33(18):2072–2083.
   PubMed Web of Science ®Google Scholar
• Saygin C, Hirsch C, Przychodzen B, et al. Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. Blood Cancer J. 2018;8(1):4.
   PubMedGoogle Scholar
• Mills K. Persistence of DNMT3A does not influence clinical outcome in acute myeloid leukaemia. Br J Haematol. 2016;175(2):185–186.
   PubMed Web of Science ®Google Scholar
• Bhatnagar B, Eisfeld AK, Nicolet D, et al. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia. Br J Haematol. 2016;175(2):226–236.
   PubMed Web of Science ®Google Scholar
• Gaidzik VI, Weber D, Paschka P, et al. DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia. Leukemia. 2018;32(1):30–37.
   PubMed Web of Science ®Google Scholar
• Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet. 1998;19(3):219–220.
   PubMed Web of Science ®Google Scholar
• Robertson KD, Uzvolgyi E, Liang G, et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 1999;27(11):2291–2298.
   PubMed Web of Science ®Google Scholar
• Xie S, Wang Z, Okano M, et al. Cloning, expression and chromosome locations of the human DNMT3 gene family. Gene. 1999;236(1):87–95.
   PubMed Web of Science ®Google Scholar
• Yin B, Chen Y, Zhu N, et al. Cloning of full-length Dnmt3b cDNA and its alternative splicing isoforms in mouse embryo. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1999;21(6):431–438.
   PubMedGoogle Scholar
• Tajima S, Suetake I, Takeshita K, et al. Domain structure of the Dnmt1, Dnmt3a, and Dnmt3b DNA methyltransferases. Adv Exp Med Biol. 2016;945:63–86.
   PubMed Web of Science ®Google Scholar
• Qiu C, Sawada K, Zhang X, et al. The PWWP domain of mammalian DNA methyltransferase Dnmt3b defines a new family of DNA-binding folds. Nat Struct Biol. 2002;9(3):217–224.
   PubMedGoogle Scholar
• Wang L, Wang J, Sun S, et al. A novel DNMT3B subfamily, DeltaDNMT3B, is the predominant form of DNMT3B in non-small cell lung cance r. Int J Oncol. 2006;29(1):201–207.
   PubMed Web of Science ®Google Scholar
• Wang J, Bhutani M, Pathak AK, et al. Delta DNMT3B variants regulate DNA methylation in a promoter-specific manner. Cancer Res. 2007;67(22):10647–10652.
   PubMed Web of Science ®Google Scholar
• Ostler KR, Davis EM, Payne SL, et al. Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins. Oncogene. 2007;26(38):5553–5563.
   PubMed Web of Science ®Google Scholar
• Horii T, Suetake I, Yanagisawa E, et al. The Dnmt3b splice variant is specifically expressed in in vitro-manipulated blastocysts and their derivative ES cells. J Reprod Dev. 2011;57(5):579–585.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan S, Van Emburgh BO, Shan J, et al. A novel DNMT3B splice variant expressed in tumor and pluripotent cells modulates genomic DNA methylation patterns and displays altered DNA binding. Mol Cancer Res. 2009;7(10):1622–1634.
   PubMed Web of Science ®Google Scholar
• Singh P, Sailu S, Palchamy E, et al. Identification of a novel leukemic-specific splice variant of DNMT3B and its stability. Med Oncol. 2017;34(8):145.
   PubMed Web of Science ®Google Scholar
• Gordon CA, Hartono SR, Cá¦Din F. Inactive DNMT3B splice variants modulate de novo DNA methylation. PLoS ONE. 2013;8(7):e69486.
   PubMed Web of Science ®Google Scholar
• Shah MY, Vasanthakumar A, Barnes NY, et al. DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. Cancer Res. 2010;70(14):5840–5850.
   PubMed Web of Science ®Google Scholar
• Ostler KR, Yang Q, Looney TJ, et al. Truncated DNMT3B isoform DNMT3B7 suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastoma. Cancer Res. 2012;72(18):4714–4723.
   PubMed Web of Science ®Google Scholar
• Plourde KV, Labrie Y, Ouellette G, et al. Genome-wide methylation analysis of DNMT3B gene isoforms revealed specific methylation profiles in br east cell lines. Epigenomics. 2016;8(9):1209–1226.
   PubMed Web of Science ®Google Scholar
• Duymich CE, Charlet J, Yang X, et al. DNMT3B isoforms without catalytic activity stimulate gene body methylation as accessory proteins in s omatic cells. Nat Commun. 2016;7(1):11453.
   PubMedGoogle Scholar
• Mizuno S, Chijiwa T, Okamura T, et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood. 2001;97(5):1172–1179.
   PubMed Web of Science ®Google Scholar
• Li Y, Wu SL, Bu DF, et al. The expression of DNA methyltransferase DNMT1, 3A and 3B in acute leukemia and myelodysplastic syndrome. Zhonghua Nei Ke Za Zhi. 2003;42(10):688–691.
   PubMedGoogle Scholar
• Mishra A, Liu S, Sams GH, et al. Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell. 2012;22(5):645–655.
   PubMed Web of Science ®Google Scholar
• Huang J, Yang M, Jin J. Effects of uroacitides on the methylation of PTEN gene in myelodysplastic syndrome cells and its mechanism. Zhonghua Xue Ye Xue Za Zhi. 2013;34:600–605.
   PubMedGoogle Scholar
• Zhang YY, Huang SH, Zhou HR, et al. Role of HOTAIR in the diagnosis and prognosis of acute leukemia. Oncol Rep. 2016;36(6):3113–3122.
   PubMed Web of Science ®Google Scholar
• Zhu LF, Chen QR, Chen SZ, et al. The construction and identification of induced pluripotent stem cells derived from acute myelogenous leukemia cells. Cell Physiol Biochem. 2017;41(4):1661–1674.
   PubMedGoogle Scholar
• Shen N, Jiang L, Li Q, et al. The epigenetic effect of microRNA in BCR-ABL1positive microvesicles during the transformation of normal hematopoietic transplants. Oncol Rep. 2017;38(5):3278–3284.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Zhang H, Wang Y, et al. Loss of Dnmt3b accelerates MLL-AF9 leukemia progression. Leukemia. 2016;30(12):2373–2384.
   PubMed Web of Science ®Google Scholar
• Li YH, Liu XD, Guo XF, et al. Expression and clinical significance of DNMT in patients with chronic myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015;23:1547–1550.
   PubMedGoogle Scholar
• Kn H, Bassal S, Tikellis C, et al. Expression analysis of the epigenetic methyltransferases and methyl-CpG binding protein families in the normal B-cell and B-cell chronic lymphocytic leukemia (CLL). Cancer Biol Ther. 2004;3:989–994.
   PubMed Web of Science ®Google Scholar
• Guo TT, Yang MZ. Expression of DNA methyltransferase genes and its significance in AML patients. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015;23(4):940–945.
   PubMedGoogle Scholar
• Oliveira LH, Schiavinato JL, Fraguas MS, et al. Potential roles of microRNA-29a in the molecular pathophysiology of T-cell acute lymphoblastic leukemia. Cancer Sci. 2015;106(10):1264–1277.
   PubMed Web of Science ®Google Scholar
• Niederwieser C, Kohlschmidt J, Volinia S, et al. Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia. 2015;29(3):567–575.
   PubMed Web of Science ®Google Scholar
• Schwind S, Marcucci G, Maharry K, et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010;116(25):5660–5669.
   PubMed Web of Science ®Google Scholar
• Kuhnl A, Valk PJ, Sanders MA, et al. Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. Blood. 2015;125(19):2985–2994.
   PubMed Web of Science ®Google Scholar
• Itonaga H, Imanishi D, Wong YF, et al. Expression of myeloperoxidase in acute myeloid leukemia blasts mirrors the distinct DNA methylation pattern involving the downregulation of DNA methyltransferase DNMT3B. Leukemia. 2014;28(7):1459–1466.
   PubMed Web of Science ®Google Scholar
• Larmonie NSD, Arentsen-Peters T, Obulkasim A, et al. MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML. Oncogene. 2018;37(1):107–115.
   PubMed Web of Science ®Google Scholar
• Vispe S, Deroide A, Davoine E, et al. Consequences of combining siRNA-mediated DNA methyltransferase 1 depletion with 5-aza-2'-deoxycytidine in human leukemic KG1 cells. Oncotarget. 2015;6:15265–15282.
   PubMedGoogle Scholar
• Chen B, Wang J, Gu X, et al. The DNMT3B -579G > T polymorphism is significantly associated with the risk of gastric cancer but not lung cancer in Chinese population. Technol Cancer Res Treat. 2017;16(6):1259–1265.
   PubMed Web of Science ®Google Scholar
• Feng X, Wang J, Gu X, et al. Association of DNMT3B -283T > C polymorphism with risk of lung and gastric cancer: a case-control study and a meta-analysis. Int J Biol Markers. 2018;33(2):195–200.
   PubMed Web of Science ®Google Scholar
• Li Y, Dai Y, Wu SL, et al. [The C46359T polymorphism of DNMT3B promoter gene and pathogenesis of acute leukemia]. Zhonghua Nei Ke Za Zhi. 2005;44(8):588–591.
   PubMedGoogle Scholar
• Zheng Q, Zeng TT, Chen J, et al. Association between DNA methyltransferases 3B gene polymorphisms and the susceptibility to acute myeloid leukemia in Chinese Han population. PLoS One. 2013;8(9):e74626.
   PubMed Web of Science ®Google Scholar
• Goncalves AC, Alves R, Baldeiras I, et al. Genetic variants involved in oxidative stress, base excision repair, DNA methylation, and folate metabolism pathways influence myeloid neoplasias susceptibility and prognosis. Mol Carcinog. 2017;56(1):130–148.
   PubMed Web of Science ®Google Scholar
• Hayette S, Thomas X, Jallades L, et al. High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia. PLoS One. 2012;7(12):e51527.
   PubMed Web of Science ®Google Scholar
• Yeh CH, Bai XT, Moles R, et al. Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia. Mol Cancer. 2016;15(1):15.
   PubMedGoogle Scholar
• Herold T, Metzeler KH, Vosberg S, et al. Acute myeloid leukemia with del(9q) is characterized by frequent mutations of NPM1, DNMT3A, WT1 and low expression of TLE4. Genes Chromosomes Cancer. 2017;56(1):75–86.
   PubMed Web of Science ®Google Scholar
• Garzon R, Liu S, Fabbri M, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009;113(25):6411–6418.
   PubMed Web of Science ®Google Scholar
• Mims A, Walker AR, Huang X, et al. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia. 2013;27(4):871–878.
   PubMed Web of Science ®Google Scholar
• Bi L, Zhou B, Li H, et al. A novel miR-375-HOXB3-CDCA3/DNMT3B regulatory circuitry contributes to leukemogenesis in acute myeloid leukemia. BMC Cancer. 2018;18(1):182.
   PubMedGoogle Scholar
• Li ZY, Yang L, Liu XJ, et al. The long noncoding RNA MEG3 and its target miR-147 regulate JAK/STAT pathway in advanced chronic myeloid leukemia. Ebiomedicine. 2018;34:61–75.
   PubMed Web of Science ®Google Scholar
• Palamarchuk A, Yan PS, Zanesi N, et al. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci USA. 2012;109(7):2555–2560.
   PubMed Web of Science ®Google Scholar
• Masetti R, Bertuccio SN, Astolfi A, et al. Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene. J Hematol Oncol. 2017;10(1):26
   PubMedGoogle Scholar
• Jiang S, Ma X, Huang Y, et al. Reactivating aberrantly hypermethylated p15 gene in leukemic T cells by a phenylhexyl isothiocyanate mediated inter-active mechanism on DNA and chromatin. J Hematol Oncol. 2010;3(1):48.
   PubMedGoogle Scholar
• Schemionek M, Kharabi Masouleh B, Klaile Y, et al. Identification of the adapter molecule MTSS1 as a potential oncogene-specific tumor suppressor in acute myeloid leukemia. PLoS One. 2015;10(5):e0125783.
   PubMed Web of Science ®Google Scholar
• Cheng J, Li Y, Liu S, et al. CXCL8 derived from mesenchymal stromal cells supports survival and proliferation of acute myeloid leukemia cells through the PI3K/AKT pathway. FASEB J. 2019;33(4):4755–4764.
   PubMed Web of Science ®Google Scholar
• Liu Q, Ma H, Sun X, et al. The regulatory ZFAS1/miR-150/ST6GAL1 crosstalk modulates sialylation of EGFR via PI3K/Akt pathway in T-cell acute lymphoblastic leukemia. J Exp Clin Cancer Res. 2019;38(1):199.
   PubMed Web of Science ®Google Scholar
• Gianfelici V, Messina M, Paoloni F, et al. IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies. Leuk Lymphoma. 2019;60(3):829–832.
   PubMed Web of Science ®Google Scholar
• Lipka DB, Witte T, Toth R, et al. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. Nat Commun. 2017;8(1):2126.
   PubMedGoogle Scholar
• McMahon CM, Ferng T, Canaani J, et al. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 2019;9(8):1050.
   PubMed Web of Science ®Google Scholar
• Schulze I, Rohde C, Scheller-Wendorff M, et al. Increased DNA methylation of Dnmt3b targets impairs leukemogenesis. Blood. 2016;127(12):1575–1586.
   PubMed Web of Science ®Google Scholar
• Cole CB, Verdoni AM, Ketkar S, et al. PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia. J Clin Invest. 2015;126(1):85–98.
   PubMed Web of Science ®Google Scholar
• Hagemann S, Heil O, Lyko F, et al. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One. 2011;6(3):e17388.
   PubMed Web of Science ®Google Scholar
• Shen JZ, Xu CB, Fu HY, et al. Methylation of secreted frizzled related protein gene in acute leukemia patients in China. Asian Pac J Cancer Prev. 2011;12(10):2617–2621.
   PubMedGoogle Scholar
• Geng S, Yao H, Weng J, et al. Effects of the combination of decitabine and homoharringtonine in SKM-1 and Kg-1a cells. Leuk Res. 2016;44:17–24.
   PubMed Web of Science ®Google Scholar
• Andrade AF, Borges KS, Castro-Gamero AM, et al. Zebularine induces chemosensitization to methotrexate and efficiently decreases AhR gene methylation in childhood acute lymphoblastic leukemia cells. Anticancer Drugs. 2014;25(1):72–81.
   PubMed Web of Science ®Google Scholar
• Jiang SH, Ma XD, Huang YQ, et al. Phenylhexyl isothiocyanate induces gene p15 demethylation by down-regulating DNA methyltransferases in Molt-4 cells. Yao Xue Xue Bao. 2009;44(4):350–354.
   PubMedGoogle Scholar
• Fan LP, Shen JZ, Fu HY, et al. Effect of epigallocatechin-3-galate on human acute monocytic leukemia cell line U937 and its relevant mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010;18:286–290.
   PubMedGoogle Scholar
• Wang LP, Zhao YN, Sun X, et al. Effects of bufalin on up-regulating methylation of Wilm's tumor 1 gene in human erythroid leukemic cells. Chin J Integr Med. 2017;23(4):288–294.
   PubMed Web of Science ®Google Scholar
• Khaleghian A, Ghaffari SH, Ahmadian S, et al. Metabolism of arsenic trioxide in acute promyelocytic leukemia cells. J Cell Biochem. 2014;115(10):1729–1739.
   PubMed Web of Science ®Google Scholar
• Tholouli E, MacDermott S, Hoyland J, et al. Quantitative multiplex quantum dot in-situ hybridisation based gene expression profiling in tissue microarrays identifies prognostic genes in acute myeloid leukaemia. Biochem Biophys Res Commun. 2012;425(2):333–339.
   PubMed Web of Science ®Google Scholar